COPD市場は2024～2034年の予測期間中に大幅な拡大が見込まれるとDelveInsightが報告 |

Leading companies shaping the Chronic Obstructive Pulmonary Disease (COPD) treatment landscape include Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, Glenmark Pharmaceuticals Ltd., Dimerix Limited, ProterixBio, among others.

DelveInsight's comprehensive report, "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast–2034," delivers a thorough examination of COPD, encompassing both historical and projected epidemiological data alongside evolving market trends across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

For a detailed look at the COPD market outlook, drug adoption rates, treatment landscape, and epidemiological trends, explore: COPD Market Forecast@https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Noteworthy Highlights from the COPD Market Report

• The global COPD market was estimated at USD 16 billion in 2023 and is projected to experience substantial compound annual growth through the study period (2020–2034).
• April 2025: Sanofi and Regeneron reported that their Phase III AERIFY-1 trial for the fully human monoclonal antibody itepekimab achieved its primary goal in former smokers with poorly controlled COPD. Former smokers were classified as those who had abstained from smoking for a minimum of six months. The study, involving 1,127 participants, demonstrated a 27% decrease in moderate-to-severe acute exacerbations versus placebo over 52 weeks.
• April 2025: Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharma firm focused on asthma and COPD therapeutics, received positive guidance from a Type C meeting with the FDA's Division of Pulmonology, Allergy, and Critical Care under the Office of Immunology and Inflammation.
• March 2025: SMSbiotech achieved a pivotal milestone by securing approval to launch a Phase I clinical trial in Australia (registration: ANZCTR12624001140549p). The study will evaluate the safety and tolerability of the company's proprietary Small Mobile Stem (SMS) cell therapy for COPD — marking the first-ever human trial of this particular cell-based treatment approach.
• March 2025: Japan's Ministry of Health, Labour and Welfare granted marketing and manufacturing approval for Dupixent (dupilumab) as a treatment for COPD in adults whose condition remains inadequately managed with existing therapies.
• January 2025: Aer Therapeutics announced the dosing of the first patient in its Phase 2a proof-of-concept trial of fexlamose (formerly AER-01) for COPD, advancing its mission to develop novel inhaled therapies targeting mucus-related pulmonary diseases.
• September 2024: GSK's Nucala (mepolizumab) reached its primary endpoint in the Phase III MATINEE study for COPD. The findings showed that combining Nucala with standard inhaled maintenance therapy led to a meaningful reduction in the annualized rate of moderate-to-severe exacerbations compared to placebo.
• April 2024: Amgen provided an update on its Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in COPD, presented at the ATS 2024 International Conference. The trial — which included patients across varying eosinophil levels without baseline exclusions — showed a 17% reduction in moderate-to-severe COPD exacerbation rates versus placebo, though the outcome did not achieve statistical significance.
• January 2024: Theravance Biopharma released results from the Phase 4 PIFR-2 trial of YUPELRI® (revefenacin) inhalation solution — the only once-daily nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for COPD maintenance. The study evaluated whether YUPELRI delivered via a standard jet nebulizer offers superior pulmonary function improvement compared to Spiriva® (tiotropium) administered through a dry powder inhaler in patients with severe-to-very severe COPD and suboptimal peak inspiratory flow rate (PIFR).
• In 2023, the aggregate COPD market across the EU4 and the UK stood at roughly USD 3,361 million, with anticipated growth at a notable CAGR. Germany commanded the largest regional share, trailed by Italy, France, and Spain, while the UK represented the smallest portion.
• DelveInsight analysts estimate approximately 44.2 million diagnosed prevalent COPD cases across the 7MM (seven major markets) in 2023.
• The United States led all 7MM nations with the highest diagnosed COPD prevalence — an estimated 18.3 million cases in 2023 — a figure expected to climb throughout the forecast period owing to elevated smoking rates, improved diagnostics, and heightened patient awareness.
• Across the EU4 and UK combined, diagnosed COPD prevalence reached approximately 18.6 million cases in 2023, with substantial increases anticipated across all nations during the study timeframe.
• Japan recorded roughly 7.2 million diagnosed prevalent COPD cases in 2023, with projections indicating notable growth through 2034.
• In the UK specifically, approximately 1.7 million female and 2 million male diagnosed COPD cases were documented in 2023, with both figures expected to rise through 2034. The comparatively high prevalence among women is likely driven by genetic susceptibility, environmental exposures, and disparities in healthcare access.

Key Industry Participants

Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, Glenmark Pharmaceuticals Ltd., Dimerix Limited, ProterixBio, and others.

Key Therapeutic Candidates

Astegolimab (MSTT1041A/AMG 282/RG6149), Mepolizumab (SB240563)/NUCALA, Ensifentrine (RPL554), Itepekimab (SAR440340/REGN3500), Dupilumab (SAR231893/Dupixent), Tozorakimab (MEDI3506), Benralizumab (FASENRA), Tezepelumab (Tezspire), EP395, SelK2, Mitiperstat (AZD4831), Tanimilast (CHF6001), SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others.

• Gender-based epidemiological analysis reveals that COPD prevalence is higher among females than males in the United States.
• The COPD market is anticipated to experience robust growth, fueled by rising disease prevalence and growing public awareness over the forecast horizon. Moreover, the introduction of numerous pipeline therapies at various clinical stages is set to fundamentally reshape the COPD market landscape.

COPD Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a common, manageable, and largely preventable condition characterized by persistent respiratory symptoms and progressive airflow limitation. These abnormalities arise from damage to the airways and/or alveoli, most commonly resulting from prolonged exposure to noxious particles or gases, including tobacco smoke.

Access a complimentary sample of the COPD Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market

COPD Epidemiological Analysis

The epidemiology section delivers insights into historical, present-day, and projected disease trends spanning the seven major markets (7MM) from 2020 to 2034. By synthesizing data from multiple studies and perspectives of key opinion leaders, it identifies the underlying drivers of current and anticipated epidemiological patterns. A granular assessment of diagnosed patient populations and emerging trends is also included.

Epidemiology Segmentation

The report provides epidemiological analysis for 2020–2034 across the 7MM, segmented as follows:

• Overall COPD Prevalence
• COPD Prevalence by Disease Severity
• Gender-Stratified COPD Prevalence
• Diagnosed Cases of Episodic and Chronic COPD

Download the full report to explore the key drivers behind COPD epidemiological trends: COPD Epidemiology Forecast@https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Drug Uptake and Pipeline Development

The drug uptake section evaluates adoption rates for recently approved COPD therapies and those anticipated to launch within the study period. The analysis encompasses market uptake by individual drug, patient adoption by therapy type, and revenue performance for each treatment.

The therapeutics assessment identifies drugs achieving the fastest uptake and examines the factors underpinning their widespread use, while also benchmarking treatments by market share.

Additionally, the report profiles ongoing COPD pipeline development activities, offering valuable perspectives on therapeutic candidates at various clinical stages and the companies behind them. It tracks recent strategic developments — including partnerships, acquisitions, mergers, licensing agreements, and patent filings — relevant to emerging therapies.

Chronic Obstructive Pulmonary Disease Therapies and Key Companies

• Itepekimab/SAR440340/REGN3500: Regeneron Pharmaceuticals/Sanofi
• Dupilumab/SAR231893 (Dupixent): Regeneron Pharmaceuticals/Sanofi
• Tozorakimab (MEDI3506): AstraZeneca/MedImmune LLC
• FASENRA (Benralizumab): AstraZeneca
• Tezspire (Tezepelumab): AstraZeneca
• Astegolimab (MSTT1041A, AMG 282, RG6149): Genentech, Inc.
• SB240563 (Mepolizumab)/NUCALA: GlaxoSmithKline
• Ensifentrine (RPL554): Verona Pharma plc
• EP395: EpiEndo Pharmaceuticals
• SelK2: Tetherex Pharmaceuticals
• Mitiperstat (AZD4831): AstraZeneca
• CHF6001/Tanimilast: Chiesi Farmaceutici S.p.A.
• SNG001 (IFN-β): Synairgen Research Ltd.
• Acumapimod (BCT-197): Mereo Biopharma
• Zofin: Organicell Regenerative Medicine
• PUL-042: Pulmotect, Inc.
• MV130: Inmunotek S.L.
• GSK3923868: GlaxoSmithKline
• PUR1800: PULMATRiX
• GRC 39815: GLENMARK PHARMACEUTICALS LTD
• DMX-700: Dimerix Limited

Learn more about therapies positioned to capture significant COPD market share: COPD Treatment Landscape@https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Market Strengths

COPD prevalence has been rising sharply in recent years, driven by higher smoking rates and the aging of populations across numerous countries, creating sustained demand for effective treatments.

Market Opportunities

Growing demand for fixed-dose combination therapies presents a notable opportunity, as combination treatments can enhance efficacy and extend therapeutic benefits beyond what single-agent therapies offer.

Report Scope

• Study Period: 2020–2034
• Geographic Coverage: 7MM — United States, EU5 (Germany, France, Italy, Spain, United Kingdom), and Japan
• Key Companies: Genentech, GlaxoSmithKline, Verona Pharma, Regeneron, Sanofi, MedImmune, EpiEndo, Tetherex, AstraZeneca, Chiesi Farmaceutici, Synairgen, Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inmunotek, PULMATRiX, Glenmark, Dimerix, ProterixBio, and others
• Key Therapies: Astegolimab, Mepolizumab/NUCALA, Ensifentrine, Itepekimab, Dupilumab/Dupixent, Tozorakimab, Benralizumab/FASENRA, Tezepelumab/Tezspire, EP395, SelK2, Mitiperstat, Tanimilast, SNG001, Acumapimod, Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others
• Therapeutic Assessment: Currently marketed and emerging COPD therapies
• Market Dynamics: Growth drivers and market barriers
• Competitive Intelligence: SWOT analysis, PESTLE analysis, Porter's Five Forces, BCG Matrix, market entry strategies
• Additional Insights: Unmet needs, KOL perspectives, analyst commentary, market access and reimbursement considerations

For more details on companies advancing COPD treatment, visit: COPD Clinical Trials and Therapeutic Assessment@https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Patient Share Overview
5. Market Overview at a Glance
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Country-Specific Patient Population Analysis
9. Current Treatment Practices
10. Unmet Medical Needs
11. Emerging Therapeutic Candidates
12. Market Outlook
13. Country-Level Market Analysis (2020–2034)
14. Market Access and Reimbursement Landscape
15. Market Growth Drivers
16. Market Constraints
17. Appendix
18. Research Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports

Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast - 2034

DelveInsight’s ‘COPD– Epidemiology– 2034’ report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

About DelveInsight

DelveInsight is a premier healthcare business consultancy and market research firm with an exclusive focus on the life sciences sector. The company partners with pharmaceutical organizations to deliver comprehensive, end-to-end solutions designed to enhance operational performance. Through its Healthcare Consulting Services, DelveInsight provides robust market analysis that empowers businesses to accelerate growth and navigate industry challenges with actionable, results-driven strategies.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/